Baxiva is developing the first K-antigen-targeting vaccine to prevent E. coli infections, offering the highest level of protection against UTIs and systemic infections.
| Website | https://www.baxiva.com |
| Employees | 9 (5 on RocketReach) |
| Founded | 2025 |
| Industry | Biotechnology Research |
Looking for a particular Baxiva employee's phone or email?
Tim Keys is the CEO of Baxiva.
5 people are employed at Baxiva.
Baxiva is based in Schlieren, Zurich.